SMARCA4 and neoplasm: Epigenetic modulation through these combinations could potentially reverse immune-cold tumor phenotypes, further enhancing treatment efficacy in SMARCA4-UT.22-24 Lastly, preclinical strategies, such as CDK4/6 inhibitors and ataxia telangiectasia-mutated and rad3-related (ATR) kinase inhibitors, are also being explored.25,26